deltatrials
Completed PHASE2 NCT00002160

A Multicenter Phase II/III, Placebo-Controlled Study of SNX-111 Administered Intrathecally to Cancer and AIDS Patients With Chronic Pain

Sponsor: Neurex

Conditions Cancer HIV Infections Pain
Interventions Ziconotide
Updated 6 times since 2017 Last updated: Jun 23, 2005

This PHASE2 trial investigates Cancer and HIV Infections and is currently completed. Neurex leads this study, which shows 6 recorded versions since 2026 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Neurex
Data source: NIH AIDS Clinical Trials Information Service

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Allentown, United States, Atlanta, United States, Baltimore, United States, Berkeley, United States, Boston, United States, Camden, United States, Chicago, United States, Cleveland, United States, Columbia, United States, Danbury, United States and 30 more location s